ClinicalTrials.gg
CompletedNCT01133470Updated Jun 14, 2010

Bioequivalence Study of Fexofenadine HCl 180 mg + Pseudoephedrine HCl 240 mg ER Tablets of Dr. Reddy's and Allegra D 24 Hour ER Tablets Under Fasting Conditions

A Phase 1 interventional study of Fexofenadine HCl + Pseudoephedrine HCl in Healthy, sponsored by Dr. Reddy's Laboratories Limited. Completed at 1 site in India. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2010-06-14.

Sponsored by Dr. Reddy's Laboratories Limited · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
54
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

The purpose of this study is to

  1. Compare and evaluate the single dose, crossover, bioequivalence study of Fexofenadine HCl 180 mg + Pseudoephedrine HCl 240 mg ER Tablets and Allegra-D 24 hr tablets.
  2. Monitor the adverse events and ensure the safety of subjects.
Read the detailed description

An open label, balanced, randomized, two-treatment, two-period, two-sequence, single dose, crossover bioequivalence study of Fexofenadine HCl 180 mg + Pseudoephedrine HCl 240 mg ER Tablets of Dr. Reddy's and Allegra-D 24 hour ER Tablets of Aventis Pharmaceuticals Inc., USA in healthy, adult, human subjects under fasting conditions.

02

Conditions studied

  • Healthy

Keywords

  • Bioequivalence
  • Fexofenadine Hydrochloride + Pseudoephedrine Hydrochloride
03

In context

Lead sponsor

Dr. Reddy's Laboratories Limited is the lead sponsor of 224 studies on the registry; 2 are open to participants now.

Of its 13 completed or terminated interventional studies of FDA-regulated products, 11 (85%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Human subjects aged between 18 and 45 years (including both)
  • Subjects'weight within the normal range according to normal values for the (18.5 to 24.9kgm2)with minimum of 50 kg weight.
  • Subjects with normal health as determined by personal medical history clinical examination and laboratory examinations within the clinically acceptable normal range.
  • Subjects having normal 12-lead (ECG).
  • Subjects having normal chest X-Ray (P/A view).
  • Have a negative urine screen for drugs of abuse (including amphetamines,barbiturates, benzodiazepines, marijuana, cocaine, and morphine).
  • Have negative alcohol breath test.
  • Subjects willing to adhere to the protocol requirements and to provide written .

Exclusion criteria

Exclusion Criteria:

Subjects will be excluded from the study, if they meet any of the following criteria:

  • to Fexofenadine Hydrochloride and Pseudoephedrine Hydrochloride or related drugs.
  • History or presence of significant cardiovascular, pulmonary, hepatic, renal, gastrointestinal, endocrine, immunological, dermatological, neurological or psychiatric disease or disorder.
  • History or presence of significant alcoholism or drug abuse in the past one year.
  • History or presence of significant smoking (more than 10 cigarettes or beedi's/day).
  • History or presence of significant asthma, urticaria or other allergic reactions.
  • History or presence of significant gastric and/or duodenal ulceration.
  • History or presence of significant thyroid disease, adrenal dysfunction, organic intracranial lesion such as pituitary tumour.
  • History or presence of cancer.
  • Difficulty with donating blood.
  • Difficulty in swallowing solids like tablets or capsules.
  • Systolic blood pressure less than 100 mm Hg or more than 140 mm Hg.
  • Diastolic blood pressure less than SO mm Hg or more than 90 mm Hg.
  • Pulse rate less than 50/minute or more than 100/minute.
  • Oral temperature less than 95°F or more than 98.5°F.
  • Respiratory rate less than 12/minute or more than 20/minute
  • SUbjects who have used any prescription medication, within 14 days of period 01 dosing or OTC medication within 14 days of period 01 dosing.
  • Major illness during 3 months before screening.
  • Participation in a drug research study within past 3 months.
  • Donation of blood in the past 3 months before screening.
  • Subjects who have consumed xanthine-containing products (including caffeine, theobromines, etc.) within 48 hours prior to period 01 dosing.
  • Subjects who have consumed food or beverages containing grapefruit or pomelo within 14 days prior to period 01 dosing.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
54 participants (actual)

Study arms

  • Experimental
    Fexofenadine HCl + Pseudoephedrine HCl

    Fexofenadine HCl 180 mg + Pseudoephedrine HCl 240 mg ER Tablets of Dr. Reddy's Laboratories

    Drug: Fexofenadine HCl + Pseudoephedrine HCl

  • Active comparator
    Allegra-D 24 hour ER Tablets

    Allegra-D 24 hour ER Tablets of Aventis Pharmaceuticals INC., USA.

    Drug: Fexofenadine HCl + Pseudoephedrine HCl

Interventions

  • DrugFexofenadine HCl + Pseudoephedrine HCl

    Drug pages: Fexofenadine · Pseudoephedrine

    Fexofenadine HCl 180 mg + Pseudoephedrine HCl 240 mg ER Tablets of Dr. Reddy's KLaboratories Limited

    Also known as: Allegra-D 24 hour ER Tablets

06

What researchers measure

Primary outcomes

  1. Bioequivalence based on Cmax and AUC parameters

    Time frame: 3 months

07

Study locations

1 site
  • Veeda Clinical Research Pvt. Ltd.,
    Ahmedabad, Gujrat 380015, India
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2007, a primary completion of Feb 2007 and a completion of Apr 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2010
First posted
May 28, 2010
Start
Feb 2007
Primary completionActual
Feb 2007
CompletionActual
Apr 2007
Last update
Jun 14, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 14, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01133470
First posted
May 28, 2010
Start date
Feb 2007
Primary completion
Feb 2007
Completion
Apr 2007
Last update
Jun 14, 2010

Study contacts

Dr. Dharmesh Domadia
principal investigator · Veeda Clinical Research Pvt. Ltd.,

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Fexofenadine · Pseudoephedrine

Start the discussion